公开(公告)号：EP3496761B1

公开(公告)日：2020-10-21

申请号：EP17761924.4

申请日：2017-08-07

申请人： Consorzio Interuniversitario Nazionale Per La Scienza E Tecnologia Dei Materiali ,  Universita' Degli Studi di Firenze ,  Universita' Degli Studi di Siena

发明人： MAGNANI, Agnese ,  NATIVI, Cristina ,  LEONE, Gemma ,  LAMPONI, Stefania ,  CONSUMI, Marco ,  FRAGAI, Marco ,  BALDONESCHI, Veronica ,  RICHICHI, Barbara ,  FRANCESCONI, Oscar

IPC分类号： A61K47/61 ,  A61P27/04 ,  A61P19/02

公开(公告)号：EP3496761A1

公开(公告)日：2019-06-19

申请号：EP17761924.4

申请日：2017-08-07

申请人： Consorzio Interuniversitario Nazionale Per La Scienza E La Tecnologia Dei Materiali ,  Universita' Degli Studi di Firenze ,  Università degli Studi di Siena

发明人： MAGNANI, Agnese ,  NATIVI, Cristina ,  LEONE, Gemma ,  LAMPONI, Stefania ,  CONSUMI, Marco ,  FRAGAI, Marco ,  BALDONESCHI, Veronica ,  RICHICHI, Barbara ,  FRANCESCONI, Oscar

IPC分类号： A61K47/61 ,  A61P27/04 ,  A61P19/02

摘要： The present invention describes the functionalization of sodium hyaluronate in a homogeneous phase with small molecules with proven inhibitory activity against membrane metalloproteins involved in the dry eye disease (MMP-2, MMP-9), in inflammatory processes at an osteoarticular level (MMP-12 and MMP-13) and in the formation of wrinkles (MMP-1 ). The hyaluronic acid derivative thus obtained (MMP- HA inhibitor) is useful for the medical treatment of dry eye and of inflammatory processes at the osteoarticular level, but also for the cosmetic treatment of skin blemishes due to aging processes.